BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37305391)

  • 1. Calcyclin-binding protein contributes to cholangiocarcinoma progression by inhibiting ubiquitination of MCM2.
    Zhang Y; Liu L; Luo B; Tang H; Yu X; Bao S
    Oncol Res; 2023; 31(3):317-331. PubMed ID: 37305391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MCM2 promotes the proliferation, migration and invasion of cholangiocarcinoma cells by reducing the p53 signaling pathway.
    Wang CL; Liu XY; Wang YH; Zhang Z; Wang ZD; Zhou GQ
    Yi Chuan; 2022 Mar; 44(3):230-244. PubMed ID: 35307646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long non-coding RNA MIR22HG inhibits cell proliferation and migration in cholangiocarcinoma by negatively regulating the Wnt/β-catenin signaling pathway.
    Hu X; Tan Z; Yang Y; Yang P
    J Gene Med; 2019 May; 21(5):e3085. PubMed ID: 30856284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RPL35A promotes the progression of cholangiocarcinoma by mediating HSPA8 ubiquitination.
    Zhang C; Wang Y; Wu G; Sun N; Bai H; Li X; Han S; Zhou H; Qi R; Zhang J
    Biol Direct; 2024 Feb; 19(1):16. PubMed ID: 38395908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of TTYH3 promotes epithelial-to-mesenchymal transition through Wnt/β-catenin signaling and inhibits apoptosis in cholangiocarcinoma.
    Xue W; Dong B; Zhao Y; Wang Y; Yang C; Xie Y; Niu Z; Zhu C
    Cell Oncol (Dordr); 2021 Dec; 44(6):1351-1361. PubMed ID: 34796468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guanine nucleotide exchange factor T exerts the cancer-promoting function in cholangiocarcinoma by enhancing the Wnt-GSK-3β-β-catenin cascade via regulation of Rac1/Cdc42.
    Wang X; Zhang X; Sun J; Sun Y; Zhang Y; He L; Wang P; Li F; Sun C
    Toxicol Appl Pharmacol; 2023 May; 467():116492. PubMed ID: 36977438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Wnt/β-catenin signaling downregulates P-glycoprotein and reverses multi-drug resistance of cholangiocarcinoma.
    Shen DY; Zhang W; Zeng X; Liu CQ
    Cancer Sci; 2013 Oct; 104(10):1303-8. PubMed ID: 23822562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic activity of retinoic acid receptor γ is exhibited through activation of the Akt/NF-κB and Wnt/β-catenin pathways in cholangiocarcinoma.
    Huang GL; Luo Q; Rui G; Zhang W; Zhang QY; Chen QX; Shen DY
    Mol Cell Biol; 2013 Sep; 33(17):3416-25. PubMed ID: 23798555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated macrophages promote Wnt/β-catenin signaling in cholangiocarcinoma cells.
    Loilome W; Bungkanjana P; Techasen A; Namwat N; Yongvanit P; Puapairoj A; Khuntikeo N; Riggins GJ
    Tumour Biol; 2014 Jun; 35(6):5357-67. PubMed ID: 24549785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wnt/β-catenin signaling as an emerging potential key pharmacological target in cholangiocarcinoma.
    Zhang GF; Qiu L; Yang SL; Wu JC; Liu TJ
    Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32140709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S100A6 protein negatively regulates CacyBP/SIP-mediated inhibition of gastric cancer cell proliferation and tumorigenesis.
    Ning X; Sun S; Zhang K; Liang J; Chuai Y; Li Y; Wang X
    PLoS One; 2012; 7(1):e30185. PubMed ID: 22295074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BMI1 promotes cholangiocarcinoma progression and correlates with antitumor immunity in an exosome-dependent manner.
    Liu Z; Hu C; Zheng L; Liu J; Li K; Li X; Wang Y; Mu W; Chen T; Shi A; Qiu B; Zhang X; Zhang Z; Xu Y
    Cell Mol Life Sci; 2022 Aug; 79(9):469. PubMed ID: 35932322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of potential targets to enhance the sensitivity of cholangiocarcinoma cells to anticancer drugs.
    Sanchon-Sanchez P; Briz O; Macias RIR; Abad M; Sanchez-Martin A; Marin JJG; Lozano E
    Biomed Pharmacother; 2023 Dec; 168():115658. PubMed ID: 37832404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GSG2 knockdown suppresses cholangiocarcinoma progression by regulating cell proliferation, apoptosis and migration.
    Zhou J; Nie W; Yuan J; Zhang Z; Mi L; Wang C; Huang R
    Oncol Rep; 2021 Jun; 45(6):. PubMed ID: 33846801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Forced overexpression of FBP1 inhibits proliferation and metastasis in cholangiocarcinoma cells via Wnt/β-catenin pathway.
    Zhao W; Yang S; Chen J; Zhao J; Dong J
    Life Sci; 2018 Oct; 210():224-234. PubMed ID: 30193944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterozygous calcyclin-binding protein/Siah1-interacting protein (CACYBP/SIP) gene pathogenic variant linked to a dominant family with paucity of interlobular bile duct.
    Kanno M; Suzuki M; Tanikawa K; Numakura C; Matsuzawa SI; Niihori T; Aoki Y; Matsubara Y; Makino S; Tamiya G; Nakano S; Funayama R; Shirota M; Nakayama K; Mitsui T; Hayasaka K
    J Hum Genet; 2022 Jul; 67(7):393-397. PubMed ID: 35087201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcyclin-binding protein inhibits proliferation, tumorigenicity, and invasion of gastric cancer.
    Ning X; Sun S; Hong L; Liang J; Liu L; Han S; Liu Z; Shi Y; Li Y; Gong W; Zhang S; Chen Y; Guo X; Cheng Y; Wu K; Fan D
    Mol Cancer Res; 2007 Dec; 5(12):1254-62. PubMed ID: 18171983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CacyBP/SIP inhibits the migration and invasion behaviors of glioblastoma cells through activating Siah1 mediated ubiquitination and degradation of cytoplasmic p27.
    Yan S; Li A; Liu Y
    Cell Biol Int; 2018 Feb; 42(2):216-226. PubMed ID: 29024247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Annexin A1 Is a Potential Prognostic Marker for, and Enhances the Metastasis of, Cholangiocarcinoma.
    Kotepui KU; Obchoei S; Vaeteewoottacharn K; Okada S; Wongkham S; Sawanyawisuth K
    Asian Pac J Cancer Prev; 2022 Feb; 23(2):715-721. PubMed ID: 35225485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Smad4-MYO18A-PP1A complex regulates β-catenin phosphorylation and pemigatinib resistance by inhibiting PAK1 in cholangiocarcinoma.
    Liu J; Ren G; Li K; Liu Z; Wang Y; Chen T; Mu W; Yang X; Li X; Shi A; Zhao W; Xu B; Chang J; Guo S; Pan C; Zhou T; Zhang Z; Xu Y
    Cell Death Differ; 2022 Apr; 29(4):818-831. PubMed ID: 34799729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.